SCarletRoAD Trial of Gantenerumab in Prodromal Alzheimer’s Discontinued

SCarletRoAD Trial of Gantenerumab in Prodromal Alzheimer’s Discontinued
German biotechnology company, MorphoSys, was informed by its partner, Swiss global health-care company, Roche, about their decision to discontinue gantenerumab's Phase III SCarletRoAD trial for prodromal Alzheimer's Disease patients. This decision is supported by a recommendation from the Independent Data Monitoring Committee, and by a pre-planned futility assessment. According to Roche, the trial was a lacking sufficient safety parameters. The Phase III trial of gantenerumab, Marguerite RoAD, for patients with mild Alzheimer's Disease, however, will still push through. The Chief Scientific Officer of MorphoSys, Dr. Marlies Sproll, commented in a press release: "The discontinuation of the SCarletRoAD study is regrettable. Nevertheless, two trials in patients with mild Alzheimer's Disease and in genetically pre-disposed individuals are continuing. MorphoSys has a very broad clinical pipeline including three programs in pivotal studies and ten in phase 2 trials. Due to the breadth of our pipeline we are not dependent on the outcome of individual trials and compounds in development." MorphoSys, thanks to its expertise, resources and strategic partnerships, has an impressive list of antibody drug candidates, desi
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *